Reata announces patient enrollment in clinal trial of Bardoxolone Methyl
Category: #healthcare  By Akshay Kedari  Date: 2019-06-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Reata announces patient enrollment in clinal trial of Bardoxolone Methyl

Reata Pharmaceuticals, a clinical-stage biopharmaceutical company recently announced enrollment of first patient in the Phase 3 FALCON trial of bardoxolone in patients with ADPKD (autosomal dominant polycystic kidney disease), cites source.

For the record, Bardoxolone is an experimental oral activator of NrF2, that induces molecular pathways to restore mitochondrial functioning, inhibiting pro-inflammatory signaling & reducing oxidative stress. The drug has been granted orphan drug designation to treat pulmonary arterial hypertension & Alport syndrome by FDA.

Warren Huff, Reata’s Chief Executive Officer & President was reportedly quoted saying that autosomal dominant polycystic kidney disease is a commonly inherited form of chronic kidney disease.  Even with standard treatment, by 60 years of age, approximately 50% of the ADPKD patients will progress to end-stage kidney disease.

Huff added that significant improvements have been observed in kidney functions in the Phase 2 PHOENIX study of ADPKD cohort. Historically, strong correlations are observed between eGFR after 12 weeks of Bardoxolone Methyl treatment & 1 year retained eGFR benefits in other forms of chronic kidney diseases. Bardoxolone Methyl is expected to serve as a meaningful treatment option for patients with autosomal dominant polycystic kidney disease.

FALCON is an international trial that is studying efficiency & safety of Bardoxolone Methyl in 300 patients with autosomal dominant polycystic kidney disease, randomized evenly to active or placebo drug. The trial is expected to enroll a broad range of patients of age 18-70 years, with an estimated eGFR (estimated glomerular filtration rate) between 30-90 ml/min/1.73 m2. 

The chief efficacy endpoint for FALCON is change from baseline estimated glomerular filtration rate compared to placebo after 48 weeks of treatment, which is followed by a 4-week drug withdrawal period, also known as retained eGFR benefit. Based upon guidance from USFDA, an analysis of retained eGFR indicating an improvement than placebo after 1 year of bardoxolone treatment might aid approval. Also, an improvement than placebo after 2 years of treatment, might aid full approval.

Source credits : https://www.globenewswire.com/news-release/2019/05/30/1859256/0/en/Reata-Announces-First-Patient-Enrolled-in-Phase-3-FALCON-Trial-of-Bardoxolone-Methyl-for-the-Treatment-of-Autosomal-Dominant-Polycystic-Kidney-Disease.html

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Guangzhou Automobile investment in Nio will be capped at $150m
Guangzhou Automobile investment in Nio will be capped at $150m
By Akshay Kedari

Nio had indicated an urgent need to secure funds and early talks with Guangzhou Auto   ...

Moderna adds two candidates in new autoimmune therapeutic area
Moderna adds two candidates in new autoimmune therapeutic area
By Akshay Kedari

Moderna, Inc., a Cambridge, Massachusetts-based biotechnology firm that is focused on drug discovery...

Guardant and NRG Oncology initiate NRG-GI005 study in colon cancer
Guardant and NRG Oncology initiate NRG-GI005 study in colon cancer
By Akshay Kedari

Survival rate for stage II colon cancer is about 58 to 88% and patients will gain from additional tr...